{"filings":[{"id":94430,"accession_number":"0001193125-26-215721","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intellia Q1 loss narrows; Phase 3 HAE data positive, rolling BLA initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $96.2M vs $114.3M YoY; revenue $15.0M (down from $16.6M).","Phase 3 HAELO topline: lonvo-z reduced HAE attacks 87% vs placebo (p<0.0001); mean monthly attack rate 0.26 vs 2.10.","Rolling BLA for lonvo-z initiated; completion H2 2026 for potential US launch H1 2027.","Cash $517.2M at Mar 31; April offering raised ~$207M gross; runway into 2028 excluding lonvo-z revenue.","FDA lifted clinical holds on nex-z Phase 3 trials (MAGNITUDE/MAGNITUDE-2); patient screening resumed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":15048000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94429,"accession_number":"0001193125-26-197489","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Intellia raises ~$194.6M in public offering of 16.7M shares at $10.75; preliminary cash $517.2M as of March 31","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 16,744,187 shares at $10.75/share; underwriters exercised full option for 2,511,628 additional shares; net proceeds ~$194.6M.","Proceeds will advance clinical development and commercial launch prep for lonvoguran ziclumeran (HAE), pipeline R&D, and potential acquisitions.","Preliminary unaudited cash, cash equivalents and marketable securities as of March 31, 2026: ~$517.2M; raised $33.6M from ATM program in Q1.","Company expects combined cash to fund expenses into 2028, excluding potential HAE product revenue, milestone payments, or strategic capital.","Potential FDA approval of lonvoguran ziclumeran for hereditary angioedema anticipated in first half of 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94428,"accession_number":"0001193125-26-179401","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intellia announces positive Phase 3 HAELO results: 87% attack reduction, 62% attack-free; starts BLA for lonvo-z","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single dose of lonvo-z reduced HAE attacks by 87% vs placebo (mean monthly rate 0.26 vs 2.10, p<0.0001) over 6 months.","62% of lonvo-z patients were entirely attack-free and therapy-free vs 11% on placebo (p<0.0001); all key secondary endpoints met.","No serious adverse events; all TEAEs mild/moderate; most common: infusion-related reactions, headache, fatigue.","Rolling BLA submission to FDA initiated; potential U.S. launch in first half of 2027 if approved.","Median follow-up 7.5 months; all lonvo-z patients remained long-term prophylaxis-free as of Feb 10, 2026 cutoff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94427,"accession_number":"0001193125-26-151300","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Intellia adopts bylaw amendments adding shareholder cure provision and exclusive federal forum clause","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Added provision allowing shareholders to cure facially apparent deficiencies in timely nomination or proposal notices.","Designated U.S. federal district courts as exclusive forum for claims under Securities Act of 1933 and Exchange Act of 1934, unless company consents otherwise.","Amendments effective April 7, 2026, adopted by Board on recommendation of nominating and corporate governance committee.","Fourth Amended and Restated Bylaws filed as Exhibit 3.1 to this Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106808,"accession_number":"0001193125-26-084309","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Intellia FDA lifts clinical hold on nex-z MAGNITUDE Phase 3 trial for ATTR-CM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA removed clinical hold on MAGNITUDE Phase 3 trial of nex-z for ATTR-CM after Grade 4 liver event on Oct 29, 2025.","Mitigation measures include enhanced liver monitoring, short-term steroid guidance, and exclusion of certain liver abnormalities.","For MAGNITUDE, added exclusion criteria for recent cardiovascular instability and ejection fraction <25%.","MAGNITUDE-2 clinical hold for ATTRv-PN was resolved in January 2026; enrollment activities resuming.","Amended ATM offering to up to $1.035B aggregate (from $750M); $635M sold, up to $400M additional shares remain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106807,"accession_number":"0001193125-26-073456","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intellia Q4 net loss $95.8M; lonvo-z Phase 3 data mid-2026; nex-z clinical hold remains for ATTR-CM","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $95.8M vs $128.9M Q4 2024; cash $605.1M, expected to fund operations into H2 2027.","Lonvo-z (HAE): HAELO Phase 3 topline data by mid-2026; BLA submission H2 2026; U.S. launch anticipated H1 2027.","Nex-z (ATTR): MAGNITUDE-2 enrollment restart underway, completion expected H2 2026; MAGNITUDE clinical hold on ATTR-CM unresolved.","Market research: 99% of HAE patients likely to take lonvo-z; 92% of physicians would prescribe.","R&D expenses $88.7M (down from $116.9M); collaboration revenue $23.0M (up from $12.9M) including $9.0M from SparingVision termination."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":67671000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106806,"accession_number":"0001193125-26-023387","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on Intellia's MAGNITUDE-2 Phase 3 trial for ATTRv-PN; MAGNITUDE hold ongoing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA removed clinical hold on IND for MAGNITUDE-2 Phase 3 trial of nex-z for ATTRv-PN, imposed Oct 29, 2025 after Grade 4 liver event and patient death.","Intellia to resume patient enrollment with enhanced liver safety monitoring; target enrollment increased from ~50 to ~60 patients.","FDA engagement ongoing for clinical hold on MAGNITUDE Phase 3 trial for ATTR-CM; no update on path forward yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106805,"accession_number":"0001193125-26-008307","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intellia provides update on FDA clinical hold for nex-z after patient death in MAGNITUDE trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Patient in MAGNITUDE Phase 3 trial for ATTR-CM died from septic shock secondary to perforated duodenal ulcer; autopsy supports clinical diagnoses.","Grade 4 liver transaminase elevations reported in <1% of >650 enrolled MAGNITUDE patients; all other cases resolved within weeks.","FDA clinical hold continues on MAGNITUDE (ATTR-CM) and MAGNITUDE-2 (ATTRv-PN) Phase 3 trials of nex-z.","No Grade 4 liver events reported in MAGNITUDE-2 (47 patients enrolled with ATTRv-PN).","Company plans to provide update after finalizing path forward with regulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123111,"accession_number":"0001193125-25-274596","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intellia reports positive lonvo-z HAE data: 97% attack-free; nex-z shows 87% TTR reduction at 36 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lonvo-z pooled Phase 1/2: 97% (31/32) attack-free and LTP-free; 75% attack-free for ≥7 months (up to 32 months).","Mean kallikrein reduction 89% at month 24; well-tolerated safety up to 3 years with no long-term risks.","Nex-z Phase 1: 87% mean serum TTR reduction at 36 months (n=9); all-cause mortality rate 3.9 vs 12.7 per 100 patient-years (HR 0.27, p=0.009) vs matched cohort.","Nex-z showed disease stability or improvement on multiple cardiomyopathy markers at 24 months; 81% stable/improved NYHA class.","FDA clinical hold on nex-z Phase 3 MAGNITUDE/MAGNITUDE-2 trials; company working to address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123110,"accession_number":"0001193125-25-269479","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intellia reports patient death in nex-z trial; awaits FDA clinical hold; lonvo-z on track","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Patient who had Grade 4 liver transaminase elevations after nex-z dose in MAGNITUDE Phase 3 trial died; FDA clinical hold letter pending.","Phase 3 HAELO trial of lonvo-z for hereditary angioedema completed enrollment; topline data expected mid-2026.","Cash, equivalents and marketable securities ~$670M as of Sept 30, 2025; company expects to fund ops into mid-2027.","Longer-term Phase 1 clinical data for nex-z in ATTR-CM to be presented Nov 10 at AHA 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123109,"accession_number":"0001193125-25-256378","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA places clinical hold on NTLA's Phase 3 nex-z trials after Grade 4 liver event","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA verbally informed Intellia of clinical hold on MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z (nexiguran ziclumeran).","Hold follows Grade 4 liver transaminases and increased total bilirubin in a MAGNITUDE patient dosed with nex-z.","Company had temporarily paused dosing/screening on Oct 27 per protocol-defined pausing criteria.","FDA will issue a formal Clinical Hold Letter within 30 days; Intellia plans to work with FDA to resolve.","NTLA (Nasdaq) stock expected to react to this regulatory setback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123108,"accession_number":"0001193125-25-250757","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intellia pauses dosing in Phase 3 MAGNITUDE trials after Grade 4 liver event in one patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient dosed on Sept 30, 2025, experienced Grade 4 liver transaminases and increased total bilirubin on Oct 24.","Patient hospitalized and receiving medical intervention; Intellia consulting experts and regulators.","Pause affects both MAGNITUDE (ATTR-CM, >650 enrolled) and MAGNITUDE-2 (ATTR-PN, 47 enrolled) trials.","Over 450 patients estimated to have been dosed with nex-z across both trials to date.","Conference call scheduled at 8:30 a.m. ET today to discuss the update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139796,"accession_number":"0001193125-25-217484","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intellia reports nex-z Phase 1 data: 92% mean TTR reduction at 24 months, 72% of patients show mNIS+7 improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean serum TTR reduction of 92% at 24 months (n=33) and 90% at 36 months (n=12) after single dose.","72% of evaluable patients (13/18) achieved ≥4-point improvement in mNIS+7 by month 24; most who had progressed on patisiran improved.","89% of all 36 patients showed improvement or stability in PND scores through 24 months; mBMI, QoL-DN, NfL all trended toward improvement.","Nex-z generally well tolerated; infusion-related reactions mild/moderate, no discontinuations; three Grade ≥3 liver enzyme elevations resolved spontaneously.","Phase 3 MAGNITUDE-2 enrollment (approx. 50 patients) expected to complete in H1 2026; BLA submission for ATTRv-PN targeted by 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139795,"accession_number":"0000950170-25-104574","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Intellia Q2 net loss narrows to $101.3M; Phase 3 enrollment ahead; CMO to retire in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $101.3M in Q2 2025 vs $147.0M a year ago; collaboration revenue $14.2M (up from $6.9M).","Cash, equivalents and marketable securities $630.5M as of June 30, expected to fund ops into H1 2027.","Phase 3 MAGNITUDE (ATTR-CM) enrollment ahead; study expanded from 765 to ~1,200 patients.","Phase 3 HAELO (HAE) randomization expected to complete in Q3 2025; BLA submission targeted H2 2026.","CMO Dr. David Lebwohl to retire effective Aug 7, 2026; will continue in role until successor appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":30872000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157384,"accession_number":"0001193125-25-141087","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intellia reports 98% reduction in HAE attacks with lonvo-z over 3 years in Phase 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single dose led to mean 98% reduction in monthly HAE attack rate across all 10 patients.","All patients attack-free and treatment-free for median 23 months at data cutoff.","No treatment-emergent serious adverse events; infusional reactions mostly Grade 1, all resolved.","Phase 3 HAELO trial screening completed ahead of schedule; >50% screened in U.S.","Expects BLA submission in 2026 and U.S. launch in 2027, pending FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157383,"accession_number":"0000950170-25-085479","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Intellia shareholders elect three Class III directors and approve 2025 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected William Chase, Georgia Keresty, and John M. Leonard as Class III directors for three-year terms ending 2028.","Approved the 2025 Equity Incentive Plan: 50.8M for, 13.6M against, 93.8K abstentions.","Ratified Deloitte & Touche as independent auditor for FY2025: 82.1M for, 497.8K against.","Advisory say-on-pay vote passed (45.8M for, 18.6M against); future votes will be held annually.","Broker non-votes were 18.3M on director elections, equity plan, and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157382,"accession_number":"0001193125-25-129524","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Intellia Therapeutics provides Phase 3 updates for NTLA-2002 and nex-z studies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HAELO study enrollment on track; expect completion Q3 2025, BLA submission H2 2026, potential US launch 2027.","MAGNITUDE-2 study of nex-z for ATTRv-PN progressing; BLA submission by 2028, potential US launch 2029.","MAGNITUDE study for nex-z in ATTR-CM enrolled ~365 of 765 patients; enrollment completion expected early 2027.","Over 200 patients dosed with nex-z in MAGNITUDE; adverse events similar to Phase 1; one asymptomatic grade 4 liver elevation resolving."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157381,"accession_number":"0001193125-25-122076","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intellia announces positive two-year Phase 1 data for nex-z in ATTRv-PN with durable TTR reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean serum TTR reduction of 90% by Day 28 remained virtually unchanged for at least 24 months in 33 patients.","14 of 18 patients showed clinically meaningful improvement (≥4 points) on mNIS+7 at 24 months.","5 of 6 patients previously on patisiran and progressing achieved improvement on mNIS+7 at 24 months.","Enrollment progressing well in Phase 3 MAGNITUDE-2 trial for ATTRv-PN; potential BLA submission by 2028.","No new drug-related adverse events; most common were mild-to-moderate infusion reactions with no discontinuations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157380,"accession_number":"0000950170-25-066403","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intellia Q1 net loss $114.3M, cash $707.1M; Phase 3 HAE enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $114.3M vs $107.4M in Q1 2024; collaboration revenue $16.6M down from $28.9M.","Cash, cash equivalents and marketable securities $707.1M as of March 31, 2025, down from $861.7M at Dec 31, 2024; expected to fund operations into H1 2027.","Phase 3 HAELO study for hereditary angioedema on track to complete enrollment in Q3 2025; BLA submission anticipated in H2 2026.","First patient dosed in Phase 3 MAGNITUDE-2 for ATTRv-PN; MAGNITUDE (ATTR-CM) enrollment ahead of projections.","RMAT designation granted for nex-z in ATTR-CM; longer-term Phase 1 data presentations planned for H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":16627000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157379,"accession_number":"0001193125-25-073904","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Intellia amends bylaws to adopt majority voting for uncontested director elections","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Majority vote standard adopted for uncontested director elections; plurality retained for contested elections.","Amended bylaws include proxy solicitation procedures consistent with SEC Rule 14a-19.","Changes effective April 3, 2025; Board approved on recommendation of governance committee.","Other clarifying and procedural amendments also made to the bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175746,"accession_number":"0000950170-25-028373","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intellia Q4 net loss $128.9M; cuts workforce 27%, ends NTLA-3001","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $128.9M vs $132.2M prior year; revenue $12.9M.","Ended 2024 with $861.7M cash; funding into first half of 2027.","Workforce reduction of ~27% in 2025; expects $8M severance charges.","Phase 3 HAELO (NTLA-2002) dosed first patient; BLA submission planned H2 2026.","Enrollment in MAGNITUDE (nex-z for ATTR-CM) ahead of projections, >550 patients by year end."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":57877000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175745,"accession_number":"0001193125-25-031989","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Intellia signs 12-year Cambridge lease for ~147K sq ft; terminates Waltham lease with $78M payment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New lease at 400 Technology Square, Cambridge: initial 101K sq ft, expandable to ~147K sq ft in two tranches starting Dec 2027.","Base rent $108/sq ft/year, 3% annual escalations; landlord provides up to $41.5M for tenant improvements.","Winter Street lease terminated with $78M paid in three installments (Feb 2025, Apr 2025, Jan 2026); no rent due after Jan 2025.","Lease term 12 years 3 months plus 5-year extension option; occupancy starts Jul 2025, rent begins ~14 months later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175744,"accession_number":"0001193125-25-004080","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","2.05","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Intellia restructures to focus on NTLA-2002 and nex-z, cuts 27% headcount, extends cash runway to H1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and investments of $862M as of Dec 31, 2024.","Strategic restructuring: prioritize NTLA-2002 and nex-z; discontinue NTLA-3001 and select research programs.","Net workforce reduction of approximately 27% in 2025; estimated $8M restructuring charges in Q1 2025.","Cash runway extended to first half of 2027.","CSO Laura Sepp-Lorenzino to retire Dec 31, 2025; Birgit Schultes promoted to EVP and CSO effective Jan 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192684,"accession_number":"0001193125-24-260417","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intellia Phase 1 in vivo CRISPR therapy nex-z shows disease stabilization in ATTR amyloidosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single dose of nex-z achieved mean 90% serum TTR reduction at month 12 in ATTR-CM (n=36); sustained >24 months.","81% of ATTR-CM patients stable/improved in NT-proBNP, 94% in hs-Troponin T at month 12; hospitalization rate 0.16/yr.","In ATTRv-PN, mean TTR reduction 91% at month 12 (n=33); neuropathy scores stable or improved through month 24.","Favorable safety: infusion-related reactions mild/moderate, no discontinuations; Phase 3 MAGNITUDE trials ongoing.","Data published in NEJM and presented at AHA 2024; supports hypothesis greater TTR reduction yields greater clinical benefit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192683,"accession_number":"0000950170-24-122810","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intellia Q3 net loss $135.7M; cash $944.7M; FDA clears Phase 3 for nex-z polyneuropathy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $135.7M vs $122.2M YoY; cash $944.7M (down from $1.0B at Dec 31).","FDA IND clearance for MAGNITUDE-2 Phase 3 trial of nex-z for ATTRv polyneuropathy; enrollment on track by year-end.","MAGNITUDE Phase 3 (ATTR-CM) enrollment tracking ahead; HAELO Phase 3 (HAE) actively screening.","Positive Phase 2 data for NTLA-2002: 8/11 patients attack-free after single 50mg dose; no serious AEs.","On track to dose first patient in NTLA-3001 Phase 1/2 for AATD by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":45003000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192682,"accession_number":"0001193125-24-244201","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intellia Phase 2 NTLA-2002: 8/11 patients attack-free after single dose; 77% attack reduction vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean monthly attack rate reduced by 77% (50 mg) vs placebo during weeks 1-16; 81% during weeks 5-16.","Eight of 11 patients in 50 mg arm had zero attacks over 16 weeks and remained attack-free through median 8-month follow-up.","Kallikrein protein reduction: 86% mean reduction from baseline at week 16 (50 mg) vs 55% (25 mg).","Well-tolerated; no serious AEs in NTLA-2002 arms; most common AEs were headache, fatigue, nasopharyngitis.","50 mg dose selected for global Phase 3 HAELO study, which is actively screening patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209134,"accession_number":"0000950170-24-093339","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intellia Q2 net loss widens to $147M; NTLA-2002 Phase 2 meets endpoints, Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NTLA-2002 Phase 2 for HAE met primary and all secondary endpoints; 50 mg dose selected for pivotal Phase 3, on track to start 2H 2024.","Phase 3 MAGNITUDE trial (NTLA-2001 for ATTR-CM) enrolling rapidly across >12 countries and >35 sites.","Plans to initiate Phase 3 of NTLA-2001 for ATTRv-PN by year-end and dose first patient in NTLA-3001 Phase 1/2 for AATD in 2H 2024.","Q2 2024 net loss $147.0M vs $123.7M YoY; cash $939.9M expected to fund operations into late 2026.","Appointed Edward Dulac as CFO effective July 22 and Brian Goff to board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":35892000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227012,"accession_number":"0001193125-24-168545","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Intellia Therapeutics appoints Edward Dulac as CFO; Glenn Goddard steps down June 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edward Dulac appointed EVP, CFO, and Treasurer, effective July 22, 2024.","Glenn Goddard steps down as CFO effective June 30, 2024; departure not related to any disagreement.","Michael P. Dube (CAO) to serve as interim principal financial officer until Dulac's start date.","Dulac receives $510K base salary, 40% target bonus, $100K sign-on bonus, and equity awards of ~$4.2M.","Board approved 2024 Inducement Plan reserving 850,000 shares for new employee equity grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227011,"accession_number":"0000950170-24-073709","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Intellia appoints Brian Goff to board; former Alexion commercial executive","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed as Class I director effective June 13, 2024; term through 2026 annual meeting.","Goff is CEO of Agios Pharmaceuticals; over 30 years biopharma commercial experience including EVP at Alexion.","Received option for 22,297 shares at $25.96 and 15,409 RSUs, vesting over three years.","Appointed to Compensation and Talent Development Committee; independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227010,"accession_number":"0000950170-24-073116","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Intellia shareholders approve officer liability limitation, re-elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment limiting officer liability under DGCL; 69M for, 2.9M against.","Fred Cohen and Frank Verwiel re-elected as Class II directors with 65.4M and 55.8M votes for, respectively.","Deloitte & Touche ratified as auditor for FY2024; 83.5M for, 256.7K against.","Say-on-pay proposal passed with 70.4M for, 1.5M against.","Certificate of Second Amendment filed with Delaware Secretary of State on June 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227009,"accession_number":"0000950170-24-056286","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intellia Q1 net loss $107M; cash $953M; Phase 3 enrollment ahead; FDA alignment on ATTRv-PN trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $107.4M for Q1 2024; collaboration revenue $28.9M (up from $12.6M YoY) on $21M non-cash adjustment.","Cash and marketable securities $953.4M as of Mar 31, 2024; expected to fund operations into late 2026.","Phase 3 MAGNITUDE trial for ATTR-CM enrolling ahead of projections; over 30 patients dosed, 40+ in screening.","FDA alignment on pivotal Phase 3 design for NTLA-2001 in ATTRv-PN; study of ~50 patients to initiate by year-end.","On track to initiate NTLA-2002 Phase 3 for HAE in H2 2024; Phase 1 long-term data at EAACI June 2."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":28935000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227008,"accession_number":"0000950170-24-044424","cik":1652130,"company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Intellia appoints Michael P. Dube as principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael P. Dube, 46, appointed as principal accounting officer; currently VP and Chief Accounting Officer.","Dube joined Intellia in September 2023; previously Global Corporate Controller at Abiomed (2012-2023).","Dube is a CPA with 10 years at Deloitte & Touche in audit and assurance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1893236763.74256,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}